Logo image of XGN

EXAGEN INC (XGN) Stock Fundamental Analysis

NASDAQ:XGN - Nasdaq - US30068X1037 - Common Stock - Currency: USD

6.14  -0.09 (-1.44%)

Fundamental Rating

2

XGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. XGN may be in some trouble as it scores bad on both profitability and health. XGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

XGN had negative earnings in the past year.
XGN had a negative operating cash flow in the past year.
XGN had negative earnings in each of the past 5 years.
In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

XGN has a better Return On Assets (-33.82%) than 62.01% of its industry peers.
XGN has a Return On Equity of -158.44%. This is in the lower half of the industry: XGN underperforms 65.02% of its industry peers.
Industry RankSector Rank
ROA -33.82%
ROE -158.44%
ROIC N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

The Gross Margin of XGN (59.51%) is better than 77.03% of its industry peers.
XGN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for XGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
XGN has more shares outstanding than it did 1 year ago.
XGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XGN is higher compared to a year ago.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

XGN has an Altman-Z score of -6.46. This is a bad value and indicates that XGN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of XGN (-6.46) is worse than 65.90% of its industry peers.
A Debt/Equity ratio of 2.09 is on the high side and indicates that XGN has dependencies on debt financing.
XGN's Debt to Equity ratio of 2.09 is on the low side compared to the rest of the industry. XGN is outperformed by 81.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.09
Debt/FCF N/A
Altman-Z -6.46
ROIC/WACCN/A
WACC10.1%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

XGN has a Current Ratio of 2.70. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.70, XGN is not doing good in the industry: 68.20% of the companies in the same industry are doing better.
XGN has a Quick Ratio of 2.70. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
XGN has a worse Quick ratio (2.70) than 66.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.7
Quick Ratio 2.7
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

XGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.06%, which is quite impressive.
XGN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.88%.
The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)38.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.48%
Revenue 1Y (TTM)5.88%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%-0.8%

3.2 Future

XGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.41% yearly.
The Revenue is expected to grow by 13.60% on average over the next years. This is quite good.
EPS Next Y31.86%
EPS Next 2Y29.6%
EPS Next 3Y21.21%
EPS Next 5Y17.41%
Revenue Next Year15.8%
Revenue Next 2Y15.95%
Revenue Next 3Y15.01%
Revenue Next 5Y13.6%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

XGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

XGN's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.6%
EPS Next 3Y21.21%

More info and screens

0

5. Dividend

5.1 Amount

XGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXAGEN INC

NASDAQ:XGN (5/1/2025, 4:30:02 PM)

6.14

-0.09 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-11 2025-03-11/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners45.44%
Inst Owner Change-0.08%
Ins Owners9.17%
Ins Owner Change10.76%
Market Cap109.91M
Analysts82
Price Target6.89 (12.21%)
Short Float %0.62%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.12%
Min EPS beat(2)4.4%
Max EPS beat(2)23.84%
EPS beat(4)4
Avg EPS beat(4)32.58%
Min EPS beat(4)4.4%
Max EPS beat(4)54.08%
EPS beat(8)8
Avg EPS beat(8)32.58%
EPS beat(12)10
Avg EPS beat(12)21.53%
EPS beat(16)13
Avg EPS beat(16)18.55%
Revenue beat(2)0
Avg Revenue beat(2)-5.54%
Min Revenue beat(2)-8.71%
Max Revenue beat(2)-2.37%
Revenue beat(4)2
Avg Revenue beat(4)2.87%
Min Revenue beat(4)-8.71%
Max Revenue beat(4)13.56%
Revenue beat(8)6
Avg Revenue beat(8)13.02%
Revenue beat(12)9
Avg Revenue beat(12)14.68%
Revenue beat(16)12
Avg Revenue beat(16)12.06%
PT rev (1m)0%
PT rev (3m)1.25%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)15.26%
EPS NY rev (1m)0.71%
EPS NY rev (3m)16%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.76%
Revenue NY rev (1m)-2.8%
Revenue NY rev (3m)-1.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.98
P/FCF N/A
P/OCF N/A
P/B 11.52
P/tB 11.52
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS3.11
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.82%
ROE -158.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.51%
FCFM N/A
ROA(3y)-43.47%
ROA(5y)-34.69%
ROE(3y)-124.78%
ROE(5y)-89.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y2.18%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 2.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.87%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.7
Quick Ratio 2.7
Altman-Z -6.46
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)115%
Cap/Depr(5y)136.67%
Cap/Sales(3y)3.99%
Cap/Sales(5y)3.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.48%
EPS Next Y31.86%
EPS Next 2Y29.6%
EPS Next 3Y21.21%
EPS Next 5Y17.41%
Revenue 1Y (TTM)5.88%
Revenue growth 3Y4.83%
Revenue growth 5Y6.62%
Sales Q2Q%-0.8%
Revenue Next Year15.8%
Revenue Next 2Y15.95%
Revenue Next 3Y15.01%
Revenue Next 5Y13.6%
EBIT growth 1Y40.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.28%
EBIT Next 3Y32.35%
EBIT Next 5Y23.21%
FCF growth 1Y9.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.18%
OCF growth 3YN/A
OCF growth 5YN/A